Wall Street brokerages forecast that Davita Inc (NYSE:DVA) will report earnings of $1.66 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Davita’s earnings, with the highest EPS estimate coming in at $1.75 and the lowest estimate coming in at $1.42. Davita reported earnings of $0.90 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 84.4%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, February 12th.
According to Zacks, analysts expect that Davita will report full-year earnings of $5.31 per share for the current financial year, with EPS estimates ranging from $5.24 to $5.38. For the next year, analysts anticipate that the company will report earnings of $5.56 per share, with EPS estimates ranging from $5.42 to $5.87. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Davita.
Davita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $1.53 EPS for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.29. Davita had a return on equity of 19.95% and a net margin of 3.68%. The business had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.85 billion. During the same period in the previous year, the company posted $0.56 earnings per share. The business’s revenue for the quarter was up 2.0% on a year-over-year basis.
A number of institutional investors and hedge funds have recently made changes to their positions in DVA. Invesco Ltd. boosted its holdings in Davita by 56.2% in the second quarter. Invesco Ltd. now owns 3,662,685 shares of the company’s stock valued at $206,063,000 after purchasing an additional 1,317,725 shares in the last quarter. Par Capital Management Inc. boosted its holdings in Davita by 40.6% in the second quarter. Par Capital Management Inc. now owns 4,159,000 shares of the company’s stock valued at $233,985,000 after purchasing an additional 1,201,300 shares in the last quarter. Pictet Asset Management Ltd. boosted its holdings in Davita by 3,290.3% in the second quarter. Pictet Asset Management Ltd. now owns 1,132,521 shares of the company’s stock valued at $63,716,000 after purchasing an additional 1,168,020 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Davita by 1,512.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 724,095 shares of the company’s stock valued at $40,159,000 after purchasing an additional 679,199 shares in the last quarter. Finally, Wedge Capital Management L L P NC lifted its stake in Davita by 1,543.5% in the third quarter. Wedge Capital Management L L P NC now owns 619,437 shares of the company’s stock valued at $35,351,000 after buying an additional 581,746 shares during the last quarter. 94.04% of the stock is owned by hedge funds and other institutional investors.
Shares of Davita stock traded down $0.53 on Friday, reaching $72.71. 1,214,509 shares of the company were exchanged, compared to its average volume of 1,401,824. The stock’s 50 day moving average price is $68.41 and its 200-day moving average price is $59.00. The company has a debt-to-equity ratio of 4.26, a current ratio of 1.81 and a quick ratio of 1.77. The company has a market cap of $9.30 billion, a P/E ratio of 20.37, a price-to-earnings-growth ratio of 0.60 and a beta of 1.67. Davita has a 1-year low of $43.40 and a 1-year high of $73.91.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Story: What is the outlook for the FAANG stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.